Background: Bone metastatic patients with osteosarcoma have a very poor prognosis. Targeted radiation therapy has been pursued as a valid alternative. The primary end point of this study was progression-free survival (PFS) at 4 months. Results: The median PFS was 61 days (18-436 days) and the median overall survival (OS) was 189 days (31-1175 days). PFS and OS for the entire patient population were 32% [95% confidence interval (CI) 16-50] and 76% (95% CI 52-89) at 4 months, respectively. No statistical differences emerged according to 153 Sm-EDTMP administered or 24-h retained activity. One-month pain palliation was only observed in a minority of subjects and in none at 4 months.
introduction
New strategies are needed to improve the prognosis of relapsed osteosarcoma, which could not achieve surgical resection, especially for patients with high-risk features such as bone metastases whose cure rate is <15% [1] [2] [3] [4] . This concept has been pointed out in a recently published series in which longterm survivors could be found only among patients who achieved surgical remission [5] . Moreover, osteosarcoma is a relatively radioresistant tumor [6] and only transient disease control was obtained with doses of <60 grays. Such doses limit the application of external radiotherapy because of significant normal tissue toxicity.
Targeted radiation therapy has been pursued as a valid alternative and Samarium-153 ethylenediaminetetramethylene phosphonic acid ( 153 Sm-EDTMP) has been investigated as a radiopharmaceutical agent selectively delivering radiation to osteoblastic skeletal lesions, due to a high affinity for skeletal tissue and chemiabsorption in areas of enhanced activity [7] . 153 Sm has a half-life of 47 h, allowing safe administration in an outpatient setting. Due to its half-life and beta emissions, a high dose rate can be delivered to regions adjacent to enhanced osteoblastic activity over a short period of time with little residual long-term activity being left in the bone marrow [8] . 153 Sm-EDTMP was initially developed as an agent for the palliative treatment of bone metastases. The Food and Drug Administration approved 153 Sm-EDTMP in April 1998 for pain palliation in patients with bone metastasis at a standard dose of 1 mCi/kg. Thereafter, 153 Sm-EDTMP was used in highrisk osteosarcoma patients as a single or combined agent. Anderson et al. [9, 10] found that the administration of highdose 153 Sm-EDTMP (1140 MBq/kg) with autologous stem cell support is feasible, with only hematological toxicity, and its association with gemcitabine as a radiation sensitizer allows partial transient responses.
In this retrospective multicenter study, we investigated the role of 153 Sm-EDTMP followed by hematopoietic stem cell (HSC) rescue in high-risk osteosarcoma patients together with the correlation of the delivered and retained activity and the clinical outcome. The primary end point was progression-free survival (PFS), while the secondary end points were toxic effects, pain relief and the correlation between delivered and retained activity when 153 Sm-EDTMP was administered at various dosages.
materials and methods

patient selection
Eligibility criteria were: a biopsy-proven diagnosis of high-grade osteosarcoma; metachronous bone metastasis [11] ; age <50 years; normal liver, kidney and cardiac function with an ejection fraction over 50%; a white blood cell count >3 × 10 9 /l and >50 × 10 9 /l platelets; no previous treatment with 153 Sm-EDTMP; and cryopreserved HSC rescue with >2 × 10 6 /kg CD34+ cells.
Before entering the study, all patients underwent an accurate physical examination, total body computerized tomography (CT) or magnetic resonance imaging (MRI) of the primary lesion and metastatic sites and a radionuclide bone scan. All these patients were centralized at the Regina Margherita Children's Hospital (Turin) or the Institute for Cancer research and Treatment (Candiolo). The local ethical committee (EC) approved the study. Since it was the first study designed as a curative treatment, in order to monitor toxic effects, the first group of patients had to be treated with a low dosage of 
end points
The primary end point of this study was PFS [12, 13] . The first tumor restaging following treatment was assessed on day 60 and then every 2 months [14] .
The secondary end points were toxicity, according to common toxicity criteria adverse events [15] , pain palliation and dosimetry [16] [17] [18] [19] [20] [21] [22] .
treatment plan
All patients had successful peripheral blood HSC collection following cyclophophamide (4 g/m 2 ) and etoposide (600 mg/m 2 ) treatment according to the chemotherapy protocol in which patients were enrolled before radiometabolic treatment. After hematological recovery following chemotherapy, all patients underwent complete restaging by CT scan or MRI and bone scan. Sm-EDTMP was administered via slow i.v. injection in single doses and the patients were hospitalized for at least 12 h. Administered activities ranged from 150 (3 mCi/kg) to 1.140 MBq/kg (30 mCi/kg).
After administration, whole-body radioactivity was continuously measured with a time interval of 2 h through Geiger-Müller probes localized on the patient's bed; to ensure repeatable evaluations and the correct measuring position, the patient received an audible warning. The total number of measures for each patient was determined on the basis of the hospitalization time (12-42 h 
tumor response
The first tumor response was assessed on day 60 or earlier if there was a clinical suspicion of progression by a complete radiological evaluation including MRI and CT of all tumor sites and a bone scan. Thereafter, patients underwent tumor restaging at bimonthly intervals until progression.
toxicity
The hematological and extra-hematological toxic effects of 153 Sm-EDTMP administration were graded according to the National Cancer InstituteCommon Toxicity Criteria (version 3.0) [15] .
pain control
Most of our patients were under opiate treatment, mainly based on morphine together with paracetamol. The patient's symptoms and analgesic needs before treatment, after 1 week and after 1 and 4 months from treatment were registered to assess the pain palliation according to Common Terminology Criteria for Adverse Events [15] .
biodistribution and kinetics
Studies on dose evaluation in the therapeutic use of 153 Sm-EDTMP for pain palliation demonstrated that only skeletal tissues adsorb the radiopharmaceutical drug and that nonskeletal tissues sites received negligible doses. In this work, we regarded the source organ to be the bone, without distinguishing between normal bone and tumor, since total body measurements did not allow us to make a distinction between the kinetics of the two tissues. The retention curve (fraction of injected activity versus time) was obtained by normalizing every measurement to the maximum, which also identified the initial reference time. From this curve, the fraction of injected activity retained in the body after 24 h from i.v. injection is also evaluated [16] [17] [18] [19] [20] [21] [22] .
statistical analysis
Data were analyzed as of October 2010. The PFS was analyzed by KaplanMeier method [23] and the differences between curves by log-rank test [24] . PFS was defined as the length of time from study entry to the date of documented progression or death, whichever occurred first. Overall survival (OS) was calculated from the date of 153 Sm-EDTMP infusion to death for any causes. The statistical analysis for dichotomic variables was carried out through Fisher's exact test [25] . The following variables were analyzed for their impact on outcome: site of disease (bone only versus bone and extra-osseous disease), activity of (Table 1) .
At study entry, all patients had bone lesions (17 both osseous and extra-osseous; 5 only osseous). Three patients had primary refractory disease, including 1 patient with previous allogeneic HSC transplantation; 10 patients were treated at the time of first disease recurrence (one patient with secondary osteosarcoma following retinoblastoma); 7 patients at second relapse and 2 patients following a subsequent relapse. Following chemotherapy, 1 patient was in complete response, 4 patients in partial response (PR), 10 had stable disease (SD) original articles Annals of Oncology and 7 were in PD ( Table 2 ). There were no significant comorbidities. All patients were under opiate treatment.
All 22 patients were assessable for efficacy and toxicity; 15 patients were assessable for correlation between delivered and retained activity. No patients were lost at follow-up. The median follow-up was 189 days (55-1175 days). 
Sm-EDTMP administration
The 153 Sm-EDTMP activity level was ≤10 mCi/kg (≤370 MBq/ kg) for six patients, >10 to 20 mCi/kg (>370 to 740 MBq/kg) for nine patients (one female patient received a tandem infusion of 153 Sm-EDTMP at 9 mCi/kg) and >20 mCi/kg (>740 MBq/kg) for seven patients (Table 2) .
tumor response
At day 60 after 153 Sm-EDTMP infusion, 10 (45%) patients had SD and 12 (55%) progression disease. No objective response was documented. When we analyzed the tumor response for patients with bone and extra-osseous disease (combined disease) to others (bone disease only), SD was obtained in 35% of patients with combined disease and in 80% of those with other location of metastases (four patients, P = 0.98). Only 28% (two patients) of patients with PD who received samarium had tumor growth arrest compared with 46% (seven patients, P = 0.003) of those who had PR or SD following previous treatment. According to the 153 Sm-EDTMP activity administrated, SD was obtained in 83%, 33% and 28% of patients who received ≤10, >10 to 20 and >20 mCi/kg, respectively, (P = 0.77).
Finally, when we considered the 24-h retained activity (4.13 mCi/kg being the median value), SD was obtained in 71% of patients with a bone uptake lower than the median value and in 37% for patients with median higher activity.
PFS and OS
As reported in Figure 1 , the median PFS was 61 days (18-436 days) and the median OS was 189 days (31-1175 days).
PFS and OS for the entire patient population were 32% and 76% at 4 months and 9% and 50% at 6 months, respectively.
At the end of the study, one patient (in PR before 153 Sm-EDTMP treatment) with SD at day 60 and tumor progression (both osseous and extra-osseous) 14 months after treatment is still alive with active disease. One patient treated with a tandem infusion (total activity 18 mCi/kg), with SD after the first administration, had osseous progression 4 months after the second one and died of disease at 34 months from the first therapy. As reported in Figures 2 and 3 , no statistical differences emerged according to the 153 Sm-EDTMP administrated or 24-h retained activity. In brief, patients who were given ≤10 mCi/kg had a median PFS of 57 days, patients with >10 to 20 mCi/kg had a median PFS of 60 days and patients with >20 mCi/kg had a median PFS of 64 days (P = 0.71). The analysis of PFS according to 24-h retained activity showed PFS of 48 (31-182 days), 54 (31-153 days) and 100 days (18-152 days) for patients with <3 mCi/kg, ≥3 to 7 mCi/kg and ≥7 mCi/kg at 24 h from treatment, respectively (P = 0.55). When we considered patients with combined disease to patients only with osseous disease, the median PFS was 61 and 114 days (P = 0.47), respectively. Patients having PD at Sm-EDTMP >20 mCi/kg to others showed a no statistically significant higher survival for the first group (50% versus 22%, P = 0.48); the role of 153 Sm-EDTMP benefits on survival was also confirmed when patients were stratified according to 24-h retained activity. OS was 379 (range 56-439) and 221 days (range 31-1175) for patients with ≥7 24-h retained activity. After HSC infusion, the median time to recover an absolute neutrophil count >0.5 × 10 9 /l was 10 days (0-37), median time to >50 × 10 9 /l platelets was 18 days (13-47) and median time to Hb >10 g/dl was 20 days (0-32). One female patient with iliac bone disease (lesion of 7.5 × 5.5 × 5 cm) did not recover until tumor progression and finally died of disease. Severe infectious complications occurred in one patient; six patients had gastrointestinal toxicity (in two cases, grade III-IV).
pain palliation after 153 Sm-EDTMP
The pain relief following 153 Sm-EDTMP was minimal because of early pain flair following radiometabolic treatment together with rapid disease progression in most cases. In brief, only 1 out of 16 assessable patients had pain relief at 1 week (6%), 9 patients (56%) at 1 month and none at 4 months.
biodistribution and kinetics and the bone uptake are completed and a second phase in which activity decreases as a single exponential function.
For the 15 patients with data available, the residual 24-h activity was calculated multiplying the fraction of injected activity for administered activity; the results are reported in Table 2 . The median time lapse was 30.3 h (range 8.7-42.9), the median residual 24-h activity was 33% (range 11%-77%) of the delivered activity, confirming a large intrapatient dependency, resulting in a median 24-h activity of 4.13 mCi/kg (range 1.37-12.46).
We did not observe any significant differences when we compared the time lapse for patients receiving ≤10, >10 to 20 or >20 mCi/kg 153 Sm-EDTMP. When we compared the 24-h retained activity, we observed significant differences between patients having received >20 mCi/kg compared with others (8.35 versus 3.08 mCi/kg, P = 0.001). Finally, when we compared the percentage of 24-h retained to the given activity, there were no significant differences [33%, 31% and 32.5% for patients receiving ≤10, >10 to 20 or >20 mCi/kg, respectively (P = NS)]. discussion This study of 22 unselected consecutive bone metastatic patients with heavily pretreated recurrent osteosarcoma confirms the poor prognosis of patients with skeletal metastatic disease from osteosarcoma.
Three recent papers reported the outcome in patients with nonmetastatic osteosarcoma, treated with surgery and chemotherapy, who first relapsed with bone metastases. The Rizzoli experience reported a 5-year OS of 13% in 52 patients with bone metastases [26] . Aung et al. [27] 
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free interval (RFI) longer than 2 years had a 5-year disease-free survival of 61% while it was only 8% in case of a shorter RFI. Jaffe et al. [28] reported that 5 of 11 patients survived 20-50 months following bone metastases.
Targeted radiotherapy with high-dose 153 Sm-EDTMP might represent an option for both its antineoplastic effect and for pain control in patients who had multifocal osteosarcoma, with no possibility of surgical removal or having progressed after first-or second-line chemotherapy [13] . High-dose 153 Sm-EDTMP for osteosarcoma patients has been proposed since 2002 by the MD Anderson group and their experience showed good tolerability together with significant low toxicity when radiometabolic treatment was followed by stem cell rescue. Other groups recently reported on osteosarcoma bone metastatic patients given low doses up to 44.8 MBq (1.21 mCi/ kg). These authors reported on 13 assessable patients in whom 5 (38%) had SD at the end of the study while the median estimates for PFS was 51 days. Thereafter, the same group treated 11 high-risk osteosarcoma patients with tandem doses of 153 Sm-EDTMP (37-51.8 and 222 MBq/kg) followed by stem cell rescue after the last infusion, with a limited toxicity and evidence of disease stabilization and tumor necrosis in 44% of patients. Nevertheless, all the patients had tumor progression with a median time of 79 days [29, 30] .
In our study,
153
Sm-EDTMP was delivered at various dosages and was followed by autologous HSC rescue. Even when administrated at >20 mCi/kg, we did not observe objective response. This would mean that, also in the case of higher 24-h retained activity, 153 Sm-EDTMP is ineffective against relapsed osteosarcoma or the residual activity is too low to be active on these particular subsets of patients. As reported by Essman et al. [31] , some areas of bone lesions may have poor 153 Sm-EDTMP uptake due to the intrinsic heterogeneity of the tumor and that could result in undertreating parts of tumor which lack bone formation. Besides, there may be some tumor cells that did not receive enough activity because of the radiobiological characteristics of a beta emitter, such as 153 Sm, in particular its pattern of energy deposition in the track of the particles and the induced DNA damage [32, 33] . The areas undertreated, due to these probable and other unknown variables, may be the ones that progress most rapidly, even in the patients having received higher 153 Sm-EDTMP. In fact, this might explain no advantage in terms of PFS compared with patients having received lower 153 Sm-EDTMP. The PFS is dramatically short even when higher doses of Sm-EDTMP treatment underwent surgery. We observed a 4-month clinical benefit for patients whose 24-h retained activity was over 7 mCi/kg, in which the 4-month PFS was 60%. However, these few patients also experienced tumor progression by day 155, except one patient who had SD for 14 months. As reported above, the analysis of OS did not significantly differ when we compared the delivered activity of 153 Sm-EDTMP to its residual 24-h activity, being 28% at 1 year. According to the MD Anderson data, the comparison of 1-year OS for patients treated with higher 153 Sm-EDTMP than others showed a higher probability of survival for the first group (50% versus 22%, P = 0.48); the role of 153 Sm-EDTMP benefits on survival was also confirmed when patients were stratified according to 24-h retained activity. We were thus able to demonstrate an OS advantage for patients with 24-h retained activity >7 mCi/kg compared with patients who had 24-h activities <3 mCi/kg or 3-7 mCi/kg (data not shown). This data should be kept in mind when patients are considered for 153 Sm-EDTMP for palliation. In such cases, a provisional bone scan with a monitoring of 24-h residual activity might suggest the earliest timing for HSC reinfusion to reduce hematological toxicity.
Despite the absence of significant extra-hematological toxicity, the benefit of this approach is minimal in regard to original articles Annals of Oncology observed responses and in terms of PFS. This remains when we also consider the uptake of 153 Sm-EDTMP; however, it should be mentioned that higher uptake means longer survival. The discrepancy in terms of OS and PFS might simply be supported by the low number of patients treated with this protocol. Furthermore, all relapsed patients underwent further therapies that might have an independent role on survival. A number of patients experienced pain flair shortly after 153 Sm-EDTMP administration, and this was followed by pain relief only for a minority of patients. Since the aggressiveness of the disease, none of the patients discontinued opiate treatment. In particular, 153 Sm-EDTMP gave a significant benefit for only 2 out of 5 pediatric patients with unresolved bone pain on analgesic drugs. Following tumor progression, some patients received external beam palliative radiotherapy, but also in these cases, it was a short-lasting benefit.
In conclusion, we found that radiometabolic treatment with 153 Sm-EDTMP followed by HSC rescue is feasible also for highly treated patients. However, its role in controlling osteosarcoma progression is minimal in a large portion of patients, even when it is administered at high dosages, and, finally, this approach offers no distinct advantages over other palliative approaches.
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